Induction chemotherapy

Phase 1

CChang Gung Memorial Hospital

Induction chemotherapy is one of 8 therapeutic programs targeting High-Risk Neuroblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

High-Risk NeuroblastomaNot yet recruiting

High-Risk NeuroblastomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in High-Risk Neuroblastoma

#DrugCompanyPhaseTrials

Unituxin

United Therapeutics

Phase 3

2 2

Leukine

Sanofi

Phase 3

1 3

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 4

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

1 5

Empaveli

Gilead

Phase 1

1 6

Dinutuximab Beta

BeiGene

Phase 1

1 7

Induction chemotherapy

CChang Gung Memorial Hospital

Phase 1

1 8

Hu14.18k322a

SSt. Jude Children's Research Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1Not yet recruiting

High-Risk Neuroblastoma

NCT07688252

Clinical

Trials by Indication[1]

High-Risk Neuroblastoma1 trial

Pilot Study of Combining of Dinutuximab-β With Induction Chemotherapy in Newly Diagnosed High Risk Neuroblastoma

Not yet recruiting·CChang Gung Memorial Hospital·Phase 1·NCT07688252·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Induction chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Induction chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chang Gung Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: CChang Gung Memorial Hospital

Induction chemotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

High-Risk Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News